Short sellers, frigates and perfume

Generali, Figeac Aero, MFE, Aquila, dormakaba, Theon, Innate Pharma, Deutz, IONOS, Commerzbank, BASF, Eiffage, Puig, TKMS, Zurich Insurance, Vusion, Verallia, PFISTERER

Short sellers, frigates and perfume

At Lux Opes, we break down companies into quick takes that get straight to the point - what is happening, why it matters, and what to watch next.

For the best reading experience, we recommend reading at Lux Opes

Financial KPIs

CompanyPriceMkt capEV/ EBITDA*P/E*Cons. upside
PFISTERER61.901,12711.4x17.5x68.6%
Verallia17.522,2355.9x16.3x19.8%
Vusion144.852,4657.1x17.2x46.1%
Zurich Insurance646.6097,782–16.4x-3.8%
TKMS75.204,77714.5x38.2x40.8%
BASF5246,0458.3x15.9x5.5%
Eiffage108.7510,6585.3x9.6x41.8%
Puig20.0411,38612.0x18.2x6.0%
Commerzbank38.1141,191–12.4x12.8%
IONOS35.084,9119.4x19.1x7.6%
Deutz7.841,8798.4x11.2x96.1%

* Next fiscal year (FY+1). Cons. upside = gap to the average 12-month analyst price target (Bloomberg consensus), not a Lux Opes view. Local currency; market cap in millions. Source: Bloomberg, analyst consensus.

All financial KPIs11 companies · 50 data rows from BloombergShow
Local currencyPFISTERERVeralliaVusionZurich InsuranceTKMSBASFEiffagePuigCommerzbankIONOSDeutz
Price and shares
Latest fiscal year2025 A2025 A2025 A2025 A2025 A2025 A2025 A2025 A2025 A2025 A2025 A
Latest period end30/0930/0630/0630/0630/0630/0930/0630/0630/0930/0930/09
52-week high113.1024.40215.00661.60108.8057147.5020.5443.3738.0213.35
52-week low54.3015.5099.95521.0057.004296.2613.7929.3220.907.47
Vs 52-week high-45.3%-28.2%-32.6%-2.3%-30.9%-8.8%-26.3%-2.4%-12.1%-7.7%-41.2%
Vs 52-week low14.0%13.0%44.9%24.1%31.9%24.0%13.0%45.3%30.0%67.8%4.9%
Volume, previous day60,37144,629136,449108,03227,318616,23041,906104,003923,77047,4526,505,473
Current price61.9017.52144.85646.6075.2052108.7520.0438.1135.087.84
Shares outstanding (m)18.1127.616.9151.263.5859.297.2563.31,073.8140.0153.4
Market value
Market cap (m)1,1272,2352,46597,7824,77746,04510,65811,38641,1914,9111,879
Total debt492,1775114,0838720,77215,3961,799181,252140455
Preferred stock––––––––3,884––
Minority interest561(6)1,765(2)1,0831,314131,710–5
Cash & equivalents364151496,7151,2184,1214,59720585,0717680
Enterprise value (m)1,1444,0582,360125,1123,64663,77922,77112,993n.m.4,9752,262
Analysts
Buy ratings621077101213799
Hold ratings–7–103966103–
Sell ratings––25–6––211
Target price (12m)104.3321.00211.67622.00105.8954.45154.2421.2442.9737.7315.39
Return potential68.6%19.8%46.1%-3.8%40.8%5.5%41.8%6.0%12.8%7.6%96.1%
Estimates
LFYSales (m)4503,3321,47269,7932,17159,65726,1195,04224,3441,3172,044
FY+15223,3001,67267,6432,49664,46025,9785,24613,1201,4202,420
FY+25873,3821,76475,6712,82465,49326,7555,92914,1501,5553,584
LFYEV/Sales2.5x1.2x1.6x1.8x1.7x1.1x0.9x2.6x–3.8x1.1x
FY+12.2x1.2x1.4x1.8x1.5x1.0x0.9x2.5x–3.5x0.9x
FY+21.9x1.2x1.3x1.7x1.3x1.0x0.9x2.2x–3.2x0.6x
LFYEBITDA (m)70810223–1897,6964,1861,110–464167
FY+1100692331–2527,6474,2791,085–529269
FY+2115744390–3087,6704,3791,219–595521
LFYEV/EBITDA16.3x5.0x10.6x–19.3x8.3x5.4x11.7x–10.7x13.5x
FY+111.4x5.9x7.1x–14.5x8.3x5.3x12.0x–9.4x8.4x
FY+210.0x5.5x6.0x–11.9x8.3x5.2x10.7x–8.4x4.3x
LFYEPS2.621.7910.0554.15–2.6211.291.012.471.460.39
FY+13.541.078.4246.841.973.2511.371.103.071.840.70
FY+23.791.6210.2352.372.663.0512.261.203.782.301.23
LFYP/E23.6x9.8x14.4x14.3x–19.7x9.8x19.8x15.4x24.4x20.3x
FY+117.5x16.3x17.2x16.4x38.2x15.9x9.6x18.2x12.4x19.1x11.2x
FY+216.3x10.8x14.2x14.6x28.2x16.9x8.9x16.7x10.1x15.3x6.4x
Growth and margins
1 YearRevenue growth17.4%-3.6%54.2%6.2%9.3%-2.9%8.8%5.3%-1.9%-15.6%12.7%
5 Year6.2%6.4%39.0%4.4%8.7%1.8%9.5%28.7%21.4%6.6%10.3%
1 YearEBITDA growth16.4%-11.8%113.0%–25.2%-11.3%6.7%33.3%–7.9%18.4%
5 Year16.4%4.7%82.2%–26.2%-5.0%11.6%24.2%–6.8%40.3%
LTMEBITDA margin17.5%26.0%17.3%–9.1%13.6%16.2%21.4%–34.8%8.8%
FY+119.2%21.0%19.8%–10.1%11.9%16.5%20.7%–37.3%11.1%
FY+219.5%22.0%22.1%–10.9%11.7%16.4%20.6%–38.2%14.5%
Balance sheet
Total debt / equity21%221%9%45%9%57%202%45%598%35%39%
Total debt / capital17%68%9%30%8%36%63%31%83%26%28%
Total debt / EBITDA0.5x2.5x0.2x–0.3x2.5x3.6x1.7x–0.3x2.3x
Net debt / EBITDA0.1x2.1x-0.3x–-3.5x2.0x2.5x1.5x–0.1x1.9x
EBITDA / interest32.6x7.3x47.2x–12.8x9.1x10.0x17.1x–11.0x7.6x

Local currency; market cap in millions. Source: Bloomberg, analyst consensus. On a phone, swipe the table sideways to see every company.


Generali (G Italy): The 2027 EPS target needs almost no growth next year, so the next plan matters more

● POSITIVE

Adjusted EPS is expected to rise more than 14% a year over 2024-26, about 30% in total, against 26-33% over the three-year plan. On the company's estimate of more than €7.6bn so far, the cash target of more than €11bn requires at most about €3.4bn in 2027.

On its own estimates for 2026, Generali has already earned most or all of its 2027 earnings target, so the promise at the Investor Day in London to exceed all targets mostly describes where it expects to stand this year. It expects adjusted EPS growth of more than 14% a year from 2024 to 2026, which means EPS about 30% higher in two years, on our arithmetic. The plan's 8-10% a year to 2027 means 26-33% over three. If the 2026 estimate holds, 2027 needs growth of only about 2.4% to reach the top of that range, and at the bottom EPS could fall about 3%. The release adds no new target and nothing beyond 2027.

Cash is ahead too. Generali estimates more than €7.6bn of net holding cash flow for the first two years of the plan, an average of more than €3.8bn a year, so the target of more than €11bn needs at most about €3.4bn in 2027. €1bn of the €1.5bn buyback has been executed. On our reading the expected surplus over the target leaves room for a larger payout or for deals in the last year of the plan, and the release does not say which Generali prefers.

The harder question is what carries growth after 2027. P&C has done much of the work, with operating result growth of 12% a year expected from 2024 to 2026, against 5% in Life. That is where the cycle may turn: at Allianz, renewal price increases were slowing, especially in large corporate risks, as we wrote on 17 Nov. Generali's answer is three growth engines, hybrid and unit-linked, SMEs and health, and more than €200m of cumulative run-rate benefit to the operating result from AI by FY2026, which the release does not split by business. Asset & Wealth Management is the steadier support, with third-party clients holding 44% of assets under management. At Allianz the same kind of business was the fastest-growing division in the third quarter, with operating profit up 35.1%. The full-year results will show whether P&C holds its pace if pricing softens as it has at Allianz.

Sources we read for this take

Company: Investor Day 2026 release (18 Nov 2026)

Peers cross-read: Allianz nine-month results, from our take of 17 Nov 2026

Our earlier take: Tires, weapons and drugs (22 Jan 2025)


Figeac Aero (FGA France): Even the bottom of the revenue range now needs the catch-up to work

● NEUTRAL

Second-half revenue has to grow at least 10% on last year to reach €530m, after 7.2% reported growth in the first half. That is about €150m a quarter, against €119.1m in the second quarter.

Figeac Aero's second quarter leaves even the bottom of its full-year revenue range resting on the catch-up it expects for the second half. First-half revenue was €230.9m, up 7.2% as reported and 8.9% organically. Last year the first half made up about 44% of the €486.8m total; on that split this year would end near €522m, below the €530-560m target the company reiterated. Reaching €530m takes €299m in the second half, about 10% more than the €271.5m of a year earlier, on our arithmetic. The midpoint takes about 16% and the top of the range 21%. That is an average of about €150-165m a quarter, against €119.1m in July to September.

The second quarter added to the load. Our September take called this a back-loaded year after a first quarter on plan. Since then organic growth in Aerospace has slowed to 8.5% in the second quarter, from 12.5% in the first. The company points to significant power outages in Tunisia, heatwaves in France and shifts in delivery timings, and expects these effects to be absorbed in the second half. On our reading the first two are lost production that overtime can recover, while delivery timings sit with customers.

Customers and peers slowed in the same quarter, which fits a sector-wide timing slip as well as Figeac's own outages. Airbus delivered 196 aircraft from July to September, fewer than the 237 of the second quarter, mostly for supply reasons, and left 323 for the last three months of its year, as we wrote in October. Montana Aerospace's revenue growth slowed to 5.9% in the quarter, against 9.7% over nine months. Parts ship months ahead of aircraft, so Airbus's delivery dip does not explain Figeac's shortfall. On our reading, a customer working to clear a year-end delivery backlog has little reason to cut parts orders, but the catch-up still runs on schedules Figeac does not set.

The order book keeps growing. The backlog rose 3.5% in the quarter to a record €5.1bn, and new business won under the PILOT 28 plan reached an annual run rate of around €54m, over 67% of the €80-100m goal, against 60% in September. The targets for March 2028, more than €600m of revenue and €100m of current EBITDA, were confirmed. What the release does not show is margin. The first-half results on 8 December will tell whether outages and heat cost profit as well as sales, against a current EBITDA target of €86-94m for the year.

Sources we read for this take

Company: H1 2026/27 revenue release (18 Nov 2026)

Peers cross-read: Airbus third-quarter deliveries, from our take of 15 Oct 2026; Montana Aerospace nine-month results, from our take of 12 Nov 2026

Track record: first-quarter figures, Aerospace growth and the back-loaded year, from our take of 3 Sep 2026

Our earlier take: Casino mergers, tyres and turnarounds (3 Sep 2026)


MFE (MFEB Italy): The third quarter shows the savings were front-loaded

● NEGATIVE

On our arithmetic third-quarter adjusted EBIT was a loss of €35.6m, against a pro forma loss of €16.4m a year earlier, and Entertainment costs fell only €42.7m in the quarter. About €100m of the nine-month cost fall comes from a new depreciation method for German TV rights.

The nine-month figures hide a third quarter that was worse than a year earlier, which is where MFE's cost story stops carrying the results. Taking the half-year figures off the nine months, group adjusted EBIT was a loss of about €35.6m in the quarter, against a pro forma loss of €16.4m a year before, and Entertainment lost about €41.5m against €12.6m. The 2025 pro forma base includes €99m of ProSiebenSat.1 disposal and restructuring charges, and the report does not say in which quarters they fell. That does not rescue the quarter: if any of them sat in the third quarter of 2025, the underlying gap is wider still. It does blur the cost trend, since part of the first-half fall may be lapping those charges. On the reported figures Entertainment costs fell €42.7m in the quarter, after €216.9m in the first half, which fits the worry in our September take that the savings were front-loaded. The nine-month headline, adjusted EBIT of €110.1m against a pro forma loss of €23.7m, had already been given by Pier Silvio Berlusconi on 11 November, so what is new sits in the interim report.

Part of the cost fall is not a saving. Since January the DACH TV rights have been depreciated on a straight-line basis instead of the run-based method used until the end of 2025, which the report says lowered depreciation by about €100m over nine months. That is a large slice of the €259.6m fall in Entertainment costs that the release sets against a savings target first put at €35-40m and later raised to €120m. Without it, the fall is about €160m, which is ahead of the €120m target, though the two do not measure the same thing. On our reading the method change shifts rights costs into later years, so the saving shrinks over time.

Revenue gives no help yet. Advertising fell 5.7% to €2,763.4m over nine months, with DACH down 9.3% and Italy and Spain down 3.3% each. In September MFE expected third-quarter advertising to fall "by low single digit"; the report says only that it "remained in negative territory". MFE has said the full year will largely depend on the fourth quarter, especially in Germany.

The outlook has narrowed. In September MFE confirmed its 2026 objective "of improving operating profitability and consolidating cash generation at Group level"; the nine-month report reaffirms only "improving operating profitability in 2026". The first is close to certain after a €133.8m gain over nine months; the cash part was the harder one. Group free cash flow was −€22.7m, Italy and Spain generated €203.6m against €348.9m, 42% less, and DACH used €226.3m. Covenant net debt rose €156m in the quarter to €1,012.9m, mostly the €153.9m dividend paid in July.

The full-year results will show whether Germany's fourth quarter turns the cash flow positive and the DACH advertising decline narrows.

Sources we read for this take

Company: 9M 2026 results release, interim financial report and results presentation (18 Nov 2026); press meeting release (11 Nov 2026); H1 2026 results release (16 Sep 2026)

Track record: front-loaded savings concern and H1 figures, from our take of 17 Sep 2026

Our earlier take: Electrification, trucks and strong catalysts (17 Sep 2026)


Aquila (AQ Romania): The margin is mending on smaller sales, the opposite of what the 2031 plan needs

● NEUTRAL

On our arithmetic the third-quarter EBITDA margin was about 4.8%, against about 4.5% a year earlier, on sales about 4% lower. The RON5.5bn revenue goal for 2031 needs close to 8% growth a year from about RON3.5bn in 2025; net debt including leases is RON464m.

Aquila's ambition for 2031 pairs a margin goal it has recently earned with a sales goal it is currently moving away from. The EBITDA margin of 5-6% compares with 5.3% of revenue in the first nine months of 2025, a figure lifted by a first half of about 5.7% on our estimate, and 4.0% in the same period of 2026. The revenue goal of about RON5.5bn is the hard part. From the roughly RON3.5bn of 2025 it needs growth of about 57%, close to 8% a year for six years, while revenue grew 2% in the first nine months of this year. The release of 16 Nov names acquisitions as one of the ways to get there and gives no split between organic growth and deals.

The margin repair so far has come with shrinking sales. Our August take said the market share Aquila had bought looked expensive until the gross margin turned, and it has begun to turn: the gross margin on goods sold was 18.7% in the third quarter, against 17.2% in the second. Taking the first-half EBITDA of RON60.5m off the nine-month RON101m leaves about RON41m for the third quarter, roughly 4.8% of about RON860m of sales. That compares with about 3.1% in the second quarter and about 4.5% a year earlier, our estimate from the first-half figures in the August take. On the same arithmetic, third-quarter sales were about 4% lower than a year earlier, so EBITDA in money terms was roughly level. The company puts the quarter's net profit of RON4.2m down to portfolio trimming and a reshaping of some costs. Aquila had talked of a gradual margin improvement in the second half in May and again in August, and the third quarter shows it, but bought with revenue, which is the reverse of what a plan built on close to 8% annual growth requires.

What the plan leaves open is how the acquisitions would be paid for. Net debt including leases was RON464m at the end of September, up from RON391m at the end of 2025, and gearing rose to 0.90 of equity from 0.74. Interest expense rose to RON16.8m in nine months from RON13.7m, and with net foreign exchange losses of RON20.1m, against RON9.4m a year earlier, the period ended with a pre-tax loss of RON2.9m. On our reading, the margin needs a few more quarters of recovery before debt-funded deals of any size look prudent, so the early years of the plan rest on organic growth and on own brands. Those grew 17% to more than RON123m in nine months, but at about 5% of revenue they move the group slowly.

Sources we read for this take

Company: Development ambition for 2031 (16 Nov 2026); Q3 2026 interim financial report (11 Nov 2026); Q3 2026 press release (12 Nov 2026)

History: H1 2026 revenue and EBITDA, their changes on H1 2025, and the second-half margin message of May and August, from our take of 13 Aug 2026

Our earlier take: Payments, commodities and eagles (13 Aug 2026)


dormakaba (DOKA Switzerland): The 14% margin goal has to absorb the acquisitions the same plan calls for

● NEUTRAL

New 2028/29 targets: an IFRS operating margin of about 14%, up from 10% in 2025/26, organic growth of 3-5% a year and another 3-5% a year from acquisitions. Organic growth was 4% in the second half of 2025/26 and in the first quarter of 2026/27, when price supplied 2.7 points.

The hard part of dormakaba's new plan sits in its own small print: the 14% margin is measured after the cost of the acquisitions the same plan asks for. The release ahead of the Capital Markets Day in London on 18 November sets an operating margin of about 14% under IFRS by 2028/29, around 400 basis points above the 10% of 2025/26, organic sales growth of 3-5% a year, another 3-5% a year from acquisitions over the cycle, cash conversion of about 100% and a return on capital above 35% at an unchanged perimeter. The targets for 2026/27 are confirmed.

The growth half is within reach on recent rates, with one caveat. Organic growth was 3.0% for 2025/26 but 4% in the second half, with North America at 5.5%, and 4.0% in the first quarter of 2026/27, the middle of the new range. The CFO cautioned in October that last year's growth was "a little back-end loaded", with a substantial part delivered in the fourth quarter, so the later quarters of this year face tougher comparisons. Our take of 8 September argued that the margin story was largely told and that growth had to rise comfortably above 3%; so far it has, though mostly through price, which contributed 2.7 points in the first quarter against 1.3 from volume.

Part of the margin step should come without operational work, though how much is unclear. The 10% is a reported figure, and on the old Swiss accounting, items affecting comparability came to CHF 53.3m at the EBITDA level in 2025/26, about 1.9% of the CHF 2,792.4m of sales; an analyst on the September call put the one-offs at 290 basis points. The bases differ, so neither is an IFRS figure, and the items were a mix: the Russian exit will not recur, acquisition costs will under the new plan. In September, before the new plan existed, the CFO said this year's improvement of at least 100 basis points would come partly from operations and partly from "lower items affecting comparability".

Acquisitions are where the target gets harder. Assa Abloy, the larger rival and a serial acquirer, grew 4% organically in the third quarter at a record EBIT margin of 17.4%, against an EBITA margin of 18.7%; the 1.3-point gap between the two is the amortisation of acquired intangibles. dormakaba's target is an IFRS operating margin, after that amortisation, so every acquired brand and customer list adds a charge inside the 14%, and the return target avoids the question by assuming an unchanged perimeter. dormakaba has also stopped reporting adjusted figures, which will make it harder for outsiders to separate lower one-offs, deal costs and better trading.

The first IFRS half-year will show the starting point. Acquisitions added 1.3 points to sales in the first quarter, short of the 3-5% a year the plan sets over the cycle. A margin above 11% while buying speeds up would make 14% look reachable; a margin that only improves when buying slows would not.

Sources we read for this take

Company: Release on new mid-term targets and Capital Markets Day (18 Nov 2026); FY 2025/26 results call (1 Sep 2026); Q1 2026/27 trading update call (28 Oct 2026)

Peers cross-read: Assa Abloy Q3 2026 call (27 Oct 2026)

Our earlier take: Streaming, DIY and cheap razors (8 Sep 2026)


Theon (THEON Netherlands): The new night-vision order covers half of what the fourth quarter has to bring in

● NEUTRAL

Nine-month book-to-bill was 0.74x against a full-year target of about 1.0x. After €160m of firm orders, about €110m is still needed by year-end if October's €45m of awards is approved, about €155m if not.

Theon's new night-vision order is too small on its own to secure the full-year order target: its firm part covers about half of the orders still needed this year, and the rest depends on approvals that the chief executive warns may slip into 2027. On 16 November Theon announced orders in Europe worth about €370m for several thousand devices, made up of about €160m of firm orders for devices, parts and follow-on support and about €210m of options. Deliveries under the firm orders are expected to start this year and continue over the next two years.

Order intake was the weak spot in the nine-month figures. Theon booked €285.2m of orders, a book-to-bill of 0.74x, and on 9 November repeated its target of about 1.0x for the full year alongside revenue guidance of about €600m. In our take of 10 November we worked out that this needs about €315m of orders in the fourth quarter alone, more than in the first nine months together, and we said the 18 November presentation should show how much of that was already signed. We have not yet reviewed that presentation, so the arithmetic below rests on the company's releases.

On our reading only the firm part counts toward this year's intake, since Theon reports options on its soft backlog as a separate line, €897m at the end of September, next to the €1,377m soft backlog itself. The firm €160m covers about 51% of the €315m. The €45m of contracts from two NATO members announced on 20 October were still subject to final approvals; once approved they take coverage to about 65% and leave roughly €110m to find, and without them the gap is about €155m. The order does little for fourth-quarter revenue either: our take of 10 November put the revenue needed in the quarter at about €217m, and deliveries on the firm orders are spread over more than two years.

The chief executive's wording is the main caveat. He said many final approvals "may be delayed" by the geopolitical situation, with some "moving into early 2027", and that demand "remains strong". We read that as preparing investors for a full-year book-to-bill below 1.0x, with part of the shortfall arriving as orders in the first quarter of 2027. The firm orders add revenue for 2027 and 2028 but leave this year's order target open, which is why we see the news as neutral.

Supply is the question the release leaves open. Theon plans to supply these orders from the remaining tube quantities under its long-term agreement with Exosens, in which it holds a 9.8% stake, and it does not say how much of that balance is left. Harder Digital, its own tube maker, now 65% owned, has a backlog of €45m including orders from within the group, and Theon says the extra investment there is to serve other night-vision contracts, not these orders. How much of the Exosens balance this contract uses, and whether a new agreement follows, is the question for the full-year results.

Sources we read for this take

Company: Orders for night vision devices worth c.€370m (16 Nov 2026); Q3 2026 / 9M 2026 trading update (9 Nov 2026); Night vision contracts worth c.€45m (20 Oct 2026)

History: fourth-quarter order and revenue requirement, from our take of 10 Nov 2026; Exosens stake, from our take of 18 Jun 2026

Our earlier take: Record coverage (10 Nov 2026)


Innate Pharma (IPH France): IPH4502 needs another year of dose work before it can prove itself

● NEGATIVE

In urothelial cancer after Padcev, the stated priority, 1 of 19 patients had a confirmed response, and none of them was dosed at the 3.6 mg/kg top dose. Dose optimisation starts in H1 2027; cash of €96.8m is guided to last to the end of Q1 2028.

The first IPH4502 data do not yet show that Innate has a drug for the patients it is aiming at, and the next answer is at least a year away. The headline response rate of 33% at the maximum tolerated dose comes from two of six patients with tumours other than urothelial cancer. In urothelial cancer after Padcev (enfortumab vedotin), the setting Innate names as its focus, 19 patients were enrolled, none at the top dose of 3.6 mg/kg, with three partial responses, only one of them confirmed. On our count that is a confirmed response rate of about 5%, or 16% if the two unconfirmed ones hold. Tumour shrinkage in most patients and an unconfirmed disease control rate of 68.4% are a reasonable start for a drug given below its top dose, but they are not response data.

Safety is the stronger part of the release. There was no febrile neutropenia, no sign of peripheral neuropathy and little hematologic toxicity, which supports Innate's case that its linker keeps the exatecan payload stable in the blood. The limit is the mouth: stomatitis was the only dose-limiting toxicity and affected 27.6% of patients, and grade 3 or worse treatment-emergent adverse events, whatever their cause, were reported in 43.4%. Splitting each dose over days 1 and 8 with mandatory prophylaxis is what the new dose-optimisation phase will test, with the first patient planned in the first half of 2027.

That timing matters because of the cash calendar. Our September take said Innate was funded to the end of the first quarter of 2028 and that its value hung on IPH4502 and on PACIFIC-9, the Phase 3 trial of monalizumab run by AstraZeneca in lung cancer. Since then AstraZeneca has moved the PACIFIC-9 readout to the first half of 2027, from the second half of 2026, and IPH4502 still needs a settled Phase 2 dose and schedule before a registrational trial can be designed. Innate had €96.8m of cash and financial assets at the end of September and keeps its cash horizon at the end of Q1 2028. PACIFIC-9 will now read out with roughly 9 to 15 months of guided cash left, and IPH4502 has no date yet for dose-optimisation data. Up to $40m of near-term Sobi milestones, noted in our September take, and the $75m still available under Innate's US at-the-market share sales facility give some room, but the latter means selling shares. Unless PACIFIC-9 is positive, funding IPH4502 beyond 2027 points to a partner or new equity. Lacutamab, partnered with Sobi, is the asset on schedule, with the first patient in the TELLOMAK-3 Phase 3 trial expected in Q1 2027 and an FDA filing planned for H2 2027.

Sources we read for this take

Company: Initial Phase 1 clinical data for IPH4502 at ENA 2026 (18 Nov 2026); Third quarter 2026 business and financial update (5 Nov 2026); PACIFIC-9 Phase 3 readout timing updated to H1 2027 (27 Oct 2026)

History: cash horizon and readout calendar, from our take of 17 Sep 2026

Our earlier take: Electrification, trucks and strong catalysts (17 Sep 2026)


Deutz (DEZ Germany): Ningi's FFG case is weak on the accounts, strong on who keeps the profit

● NEGATIVE

Ningi Research, which says it is short Deutz, claims Deutz said too little about a 45% outside owner of FFG's main unit. Deutz confirmed the 45% stake on its 5 Nov call but has not answered the disclosure claim, and is examining the report. The accounting claim reads as thin. The open question is how much of FFG's profit belongs to someone else while Deutz carries the debt.

Price 7.84  ·  P/E next yr 11.2x  ·  Consensus upside 96.1%

The short seller's case against Deutz is weakest where it is loudest, and its quieter point could cost Deutz's shareholders money. Ningi Research, which says it holds a short position in Deutz, published a report on 18 Nov attacking the takeover of the defence vehicle maker FFG, which Deutz closed earlier this month for about €1.6bn. Wallstreet-online reports that around €1bn of that was cash funded with debt. According to Ningi, as reported by Börsen-Zeitung, 45% of FFG Industries GmbH, a unit it ties to FFG's growth, belongs to a former Ukrainian member of parliament and his company, and Deutz did not disclose this. Wallstreet-online and Stuttgarter Zeitung report two further claims from Ningi. The first is that shareholders were not told before they approved about 71 million new shares in August. The second is that Deutz must share the unit's profit while it services the acquisition debt. Deutz has not confirmed who the holder is or responded to the disclosure claim, and none of the claims has been independently confirmed. In a statement on its website, Deutz said it has taken note of the report, is reviewing the claims carefully and will respond based on the relevant facts. It has given no detail yet.

The 45% stake itself came up on the third-quarter call on 5 Nov. An analyst asked about "the 45% shareholder" in FFG Industries, and the chief executive, Sebastian Schulte, confirmed "a 45% local shareholder, which is a bit of precondition to do this business". So the disclosure question is narrower than the report suggests: what shareholders were shown before the August vote. Deutz has yet to answer that.

The accounting claim looks weakest. Börsen-Zeitung summarises Ningi as saying Deutz cannot fully consolidate FFG Industries, so that more than half of the FFG revenue Deutz expects next year would drop out. Schulte said the numbers Deutz has given follow IFRS full consolidation. If Deutz controls the unit, as Schulte indicated, full consolidation is the normal treatment, and all of FFG Industries' revenue and EBITDA stay in Deutz's accounts. What leaves is part of the profit that belongs to Deutz's shareholders.

That second part is the real issue, and it bears on our own figures. In our take of 5 Nov we wrote that FFG should add over €1bn of revenue at a 20%+ EBITDA margin in 2027, which is at least €200m of EBITDA. Suppose FFG Industries is more than half of FFG's expected 2027 revenue, as Ningi says, and earns similar margins. Then roughly a fifth or more of that EBITDA (45% of over half) is earned for the minority holder, and its share of net profit and dividends would be similar. Deutz still pays the interest on the roughly €1bn of debt. Handelsblatt reports that FFG Industries held about €298m, some 60% of the group's cash, at the end of 2025. Schulte said Deutz and FFG have "full access to the cash" and called the arrangement "a cash pool". Access to that cash is not ownership of it, and he also said distributions flow according to the shareholding.

Deutz can settle most of this with numbers it already has. Schulte said on the call that the purchase price was adjusted for the minority but would not give "exact numbers", so the size of that adjustment is unknown. In September we noted that the deal could raise the share count by 57%. Shareholders who took that dilution should now be told what share of FFG's profit is theirs.

Sources we read for this take

Reported: Börsen-Zeitung (18 Nov 2026); Handelsblatt on FFG Industries' cash (18 Nov 2026); wallstreet-online (18 Nov 2026); Stuttgarter Zeitung (18 Nov 2026); dpa-AFX (18 Nov 2026)

Short seller: Ningi Research report on the FFG takeover (18 Nov 2026), as reported

Company: Statement on FFG Acquisition, deutz.com (18 Nov 2026); Q3 2026 results call (5 Nov 2026)

History: FFG revenue and margin, from our take of 5 Nov 2026; share count, from our take of 24 Sep 2026

Our earlier take: A big one (5 Nov 2026)


IONOS (IOS Germany): The next chief executive inherits a cloud arm that makes no profit yet

● NEUTRAL

SAP board member Thomas Saueressig replaces Achim Weiß on 1 April 2027. Cloud Solutions is 15% of revenue at break-even; on our arithmetic the rest earned about 43% EBITDA margins over nine months.

Price 35.08  ·  P/E next yr 19.1x  ·  Consensus upside 7.6%

The real question in IONOS's change of chief executive is how much capital the next one puts into Cloud Solutions, a business growing above 20% that makes no profit yet. Thomas Saueressig, a member of SAP's executive board, takes over on 1 April 2027 under a release of 17 November. Achim Weiß, chief executive since 2018, steps down at the end of March, and United Internet, the majority shareholder, will propose him for the supervisory board in May 2027. Five days earlier the CFO said IONOS would present updated mid-term guidance "alongside a clear capital allocation strategy next year". No date was given; if it comes with the March results, it will be set before the new chief executive is in post, and his own priorities will show later in the year.

His record covers both halves of the business. At SAP he runs the Customer Value Group, covering sales, services and delivery, and the release stresses his work on putting AI to use for customers; earlier he was chief information officer in charge of cloud transformation. The first fits the AI tools IONOS sells to micro-businesses, the second Cloud Solutions, the sovereign infrastructure business for mid-sized firms and the public sector: €158m, or 15% of nine-month revenue, growing 21.4% in the third quarter. The CFO said the unit is "at the moment" at break-even and that the focus there is revenue growth.

Our arithmetic shows what is at stake. Adjusted EBITDA was €390m on €1,055m of revenue over nine months. With cloud at break-even, the hosting, domains and AI tools, plus intercompany hosting, earned about 43% of their revenue. That core carries the group margin goal of about 40%, against 36.8% in 2025, and it has delivered: our August and October takes said the second half needed EBITDA growth of about 15%, and the third quarter brought 17%.

Capital is already moving towards cloud. Capex reached 6.7% of revenue in the first nine months against 4.1% a year earlier, most of it growth spending there, and the CFO expects a higher ratio next year as hardware prices rise. Weiß moving to the supervisory board under United Internet's control keeps the old team close, which lowers the risk of an abrupt change of course.

The open question is whether the plan under the new chief executive keeps the 40% goal while cloud grows, and whether IONOS finally shows what cloud earns, as the CFO promised through new segment reporting.

Sources we read for this take

Company: Release on the CEO change (17 Nov 2026); Q3 2026 results call (12 Nov 2026)

Reported: The Register on Saueressig's SAP roles (17 Nov 2026)

Track record: second-half EBITDA growth needed for the 2026 target, from our takes of 11 Aug and 20 Oct 2026, and Q3 delivery from our take of 12 Nov 2026

History: medium-term targets against the 2025 margin, from our take of 11 Aug 2026

Our earlier take: Coffee, biosimilars and cool cars (12 Nov 2026)


Commerzbank (CBK Germany): Brussels removes the last hurdle, and the payout now depends on UniCredit

● NEUTRAL

The EU cleared UniCredit's acquisition without conditions; only Polish approval remains. Cost cuts under UniCredit should lift earnings, but the full payout of profit that rewards today's shareholders will be set by a board UniCredit controls.

Price 38.11  ·  P/E next yr 12.4x  ·  Consensus upside 12.8%

The last competition hurdle is gone, and with it most of the leverage Commerzbank's other shareholders had. The European Commission cleared UniCredit's acquisition unconditionally on 16 November, five weeks after it was notified on 9 October. It found the two banks' combined shares in German banking "moderate", with trade finance the only exception, and judged that enough German, cooperative and international banks remain for companies to switch. Poland is the last approval outstanding, and UniCredit expects all of them by the end of November.

UniCredit is getting control without paying a control premium. Its exchange offer, designed to take it past the 30% threshold, offered 0.485 UniCredit shares per Commerzbank share, worth €30.8 and a premium of 4% when it was announced in March. That took it to just under 50%, and it plans to request an extraordinary meeting in the first quarter of 2027, where its votes would let it reshape the supervisory board and, in turn, the management board. Its plans reportedly include cutting around 7,000 jobs and shrinking the foreign network. The German state, which still holds about 13%, has called the bid "aggressive and hostile", but Brussels has now made clear that competition law gives Berlin no grounds to block it.

What changes for shareholders is who decides how the profits are used. In our take of 10 November, Commerzbank was earning a 12% return on tangible equity and planned to return about €3.2bn for 2026, the whole net result after AT1 coupons and one-offs, with a CET1 ratio of 14.2%, 370 basis points above the MDA threshold. That policy was set by a board that is about to change. A holder with half the votes has other uses for a well-capitalised bank's surplus, including paying for the restructuring that 7,000 job cuts would require.

UniCredit has done this before in Germany. After taking control of HypoVereinsbank, it had HVB transfer its 77.53% stake in Bank Austria to UniCredit in 2006, then squeezed out HVB's last 4.55% of shareholders at €38.26 a share, a price set on a valuation by its own experts under the German IDW S 1 standard and confirmed by a court-appointed auditor. Minority lawsuits delayed the cash until September 2008. For Commerzbank's remaining holders the lesson is that, once UniCredit controls the vote, what they keep is decided by valuation reports and court timetables, and assets can be moved within the group first.

The cost cuts are where the gain lies. Costs were flat at €1,677m in the third quarter on revenue of €3,199m, a cost-income ratio of about 52%, and a cut on that scale would take a large share out of the cost base over time. Whether the remaining holders share in that depends on the structure UniCredit chooses once it has control: an unchanged payout, a new offer, or an agreement that puts Commerzbank's cash at its disposal against compensation.

Sources we read for this take

Regulator: European Commission press release IP/26/2440 and Executive Vice-President Ribera's remarks (16 Nov 2026)

Reported: finews (16 Nov 2026); EUobserver (16 Nov 2026)

Company: UniCredit exchange offer release (16 Mar 2026)

History: UniCredit and HVB: Bank Austria transfer (2006), squeeze-out at €38.26 (UniCredit releases 2007-2008)

Track record: Commerzbank Q3 2026 results, from our take of 10 Nov 2026

Our earlier take: Record coverage (10 Nov 2026)


BASF (BAS Germany): Promising Evonik's jobs and sites makes a higher bid harder to justify

● NEGATIVE

Bloomberg and Reuters report that BASF is preparing a new offer and has offered to protect Evonik's jobs and German sites. We read that as negative for BASF: the price goes up while the savings that would pay for it shrink. BASF declined to comment.

Price 52  ·  P/E next yr 15.9x  ·  Consensus upside 5.5%

BASF appears ready to pay more for Evonik while giving away much of what would make the deal pay. Bloomberg reported first, and Reuters followed through two people familiar with the matter, that BASF has written to the government of North Rhine-Westphalia, the RAG Foundation and German members of parliament with possible commitments on plants, jobs and training, ahead of a new offer that could come within days. According to Bloomberg, BASF could rule out layoffs for a period still to be set and guarantee that all German production sites keep running. BASF and RAG declined to comment, so none of this is confirmed.

The arithmetic gets harder at every step. Evonik turned down €22.15 a share and then €24, roughly €11bn for the equity, and the first proposal was already put at about €14.2bn including debt. When two chemical groups with overlapping German sites merge, the savings that justify a premium come mostly from plants and overheads. Evonik's existing guarantee rules out compulsory redundancies in Germany until 2032, and its own plan for about 3,200 job cuts between 2027 and 2029 is already counted in its plans. Add a pledge to keep every German site running and BASF pays a higher premium for revenue and portfolio benefits it has not put a number on.

The commitments are aimed at the people who can say yes. RAG holds about 43.8% and its board of trustees, on which the state premier sits, has to approve any sale, while the state government still says Evonik's independence should be protected. Guarantees make it easier for RAG to accept, so they raise the odds of a deal. They do it by shifting value from BASF's shareholders to Evonik's workforce and its sellers.

There is also the question of what BASF would be paying for. Evonik's third-quarter adjusted EBITDA rose 40% to €629m, and most of the gain came from Advanced Technologies, whose margin jumped to 22.0% from 14.0% as the war in the Middle East disrupted supply chains. A higher bid set against those earnings is a premium paid on a peak that Evonik itself ties to a disruption elsewhere.

BASF also has less room than the letter implies. It has promised at least €12bn of distributions for 2025 to 2028 and wants a single A rating, and a deal of around €14bn already pressed on both. A higher price with smaller savings presses harder, and BASF has not said which goal would give way.

Sources we read for this take

Reported: Bloomberg (17 Nov 2026); Reuters (17 Nov 2026); Bloomberg on the €24 proposal (26 Oct 2026)

Company: BASF and RAG declined to comment

Target: Evonik Q3 2026 results (Lux Opes take, 3 Nov 2026)

Our earlier take: Jet engines, CDMOs and catalysts (15 Oct 2026)


Eiffage (FGR France): The EPR2 deal buys certainty of work, and the margin risk sits in the small print

● NEUTRAL

Les Echos reports that EDF is close to a civil works contract of about €14bn with Bouygues, Eiffage and Vinci for its six new reactors. For Eiffage the gain is long-dated work across all three reactor pairs, with modest growth per year. EDF says talks continue and the builders did not comment.

Price 108.75  ·  P/E next yr 9.6x  ·  Consensus upside 41.8%

For Eiffage, a share of EDF's reactor civil works would bring fifteen years of known work and little growth, and whether it earns money depends on contract terms nobody has published. Les Echos reported on 17 November that EDF is finalising a civil works contract worth about €12bn in 2020 euros, close to €14bn in today's money, for the six EPR2 reactors. The work would go to Bouygues, Eiffage and Vinci, together with the mid-sized groups NGE and Fayat, and would cover the foundations and concrete buildings. EDF's board is to approve it by the end of November. EDF told AFP only that it had received a proposal from a group of major firms and that talks continue. Vinci and Bouygues did not comment, so nothing is confirmed.

For Eiffage the change is in duration more than in size. It already holds the 2023 contract for the first pair at Penly, worth more than €4bn. A single framework would cover all three pairs, Penly, Gravelines and Bugey, because EDF wants the same methods and teams to repeat from one pair to the next. The work would run for about fifteen years. Split evenly between the three majors, €14bn over that period comes to about €0.3bn a year each, against €10.30bn of contracting revenue at Eiffage in the first half alone and an order book of €31.5bn. The contract adds certainty of work far more than it adds growth.

Our own arithmetic on price shows no discount for repetition yet. Les Echos puts the framework at about €12bn in 2020 euros, or about €4bn a pair on that basis. Eiffage's 2023 contract for the first Penly pair was worth more than €4bn in the money of its day, which would be somewhat less in 2020 euros. Like for like, the later pairs therefore cost about the same as the first, or slightly more. EDF wants each pair to get cheaper through repetition; at this price, any saving from repetition stays with the builders if their costs do fall.

The terms decide whether this is good business. EDF's own reactors at Flamanville and Hinkley Point ran far over cost and schedule, and the report does not say how overruns would be shared between EDF and the builders. A fixed price on fifteen years of nuclear concrete would put that risk on contractors whose contracting margin was 2.6% in the half.

The order also depends on money that is not yet settled. The state loan covering 60% of the cost and the contract for difference are under an in-depth EU state aid investigation, and EDF's final investment decision is expected by the end of the year. Until then, the framework is a promise of work, with no start date.

Sources we read for this take

Reported: Les Echos via Europe Business News (18 Nov 2026); Boursorama (18 Nov 2026)

Company: EDF statement to AFP (17 Nov 2026); Eiffage half-year 2026 figures as used in our prior take

History: Eiffage's 2023 Penly contract, as reported by Les Echos

Our earlier take: Energy solutions, construction and flying trains (27 Aug 2026)


Puig (PUIG Spain): Parfums de Marly fits the plan, but the price and the funding decide it

● NEUTRAL

WWD reports that Puig is in final talks to acquire Parfums de Marly. The numbers cut both ways: Marly's retail sales grew 42% last year, but Puig would pay for it with a second large cheque within months. Puig did not respond and Artessence had no comment.

Price 20.04  ·  P/E next yr 18.2x  ·  Consensus upside 6.0%

Parfums de Marly is the kind of brand Puig's plan calls for, and it would cost Puig more than the headline price suggests. WWD reported on 17 November, citing industry sources, that Puig is in final talks to acquire Parfums de Marly. Puig did not respond to a request for comment and a spokeswoman for Artessence, Marly's parent, had no comment, so nothing is confirmed. In October Reuters named CVC, Cinven and Puig as suitors, with one source putting the value at less than €2bn. Advent took its majority stake in June 2023 in a deal industry sources valued at more than $700m.

The fit with Puig's plan is plain. At its capital markets day in October Puig made niche fragrance one of four drivers of Vision 2032, which aims to take sales past €8bn by 2032 from €5.04bn in 2025. It already owns Byredo, Penhaligon's, L'Artisan Parfumeur and Dries Van Noten. Marly's retail sales passed $780m in the year to March 2026, up 42%, and the US, where Puig wants to grow its niche brands, is close to half of Artessence's business.

Two things temper that. Retail sales are what shoppers pay, while Puig would book what retailers pay it, so Marly's revenue to an owner is well below $780m, and a price close to €2bn is a higher multiple of revenue than the headline suggests. And the cheque comes soon after the last one: Puig pays €900m in cash for ISDIN at closing in the first quarter of 2027 and a further €300m in 2029, from net debt of 1.5x adjusted EBITDA before either payment. Two deals of that size within months would raise leverage while the base business slows, with second-quarter like-for-like growth at 4.1% against 7.7% a year earlier.

The category gives the deal its logic. dsm-firmenich grew its perfumery and beauty sales 8% in the third quarter, with fine fragrances up high single digits, and Interparfums returned to growth at 4.8%. Fragrance is still growing; what Puig would be paying for is the fastest-growing corner of it.

Puig is buying in growth its existing business is not producing fast enough, with like-for-like growth slowing. That can work in niche fragrance, where its own brands are growing quickly, but the price and the funding matter more than the fit.

Sources we read for this take

Reported: WWD (17 Nov 2026); Reuters via FashionUnited (29 Oct 2026); The Industry Beauty (18 Nov 2026)

Company: Puig did not respond; Artessence had no comment

Peers cross-read: dsm-firmenich Q3 2026 (5 Nov 2026) and Interparfums Q3 2026 (22 Oct 2026), Lux Opes takes

Our earlier take: Pharma, CMDs and a lot of defense (22 Sep 2026)


TKMS (TKMS Germany): Four repeat frigates bring the 7% margin target closer

● POSITIVE

Four more ships on a line already running should lift margins more than revenue. The German Navy took up its option for four more MEKO A-200 frigates; TKMS gave no contract value.

Price 75.20  ·  P/E next yr 38.2x  ·  Consensus upside 40.8%

The frigate order matters less for its size than for what it does to the margin: four more ships of a design already in production are the most profitable kind of work a shipyard can add. TKMS and the German procurement office signed the contract for four more MEKO A-200 DEU frigates on 17 November, taking the series to eight ships. None of this is a surprise: the four were an option in the original contract, and the Bundestag's budget committee approved them on 8 October. TKMS calls it the largest surface vessel order in its history but gives no value, so the size of the order intake will only show in the full-year figures.

The more useful part is in the chief executive's wording. The extra ships "will be built using the production structures already in place", the first ship is still due at the end of 2029, and the rest are to follow at short intervals. Repeat hulls on a running line are where shipbuilders earn their margin, because the design is paid for, suppliers are set and each hull goes faster than the last. This is where TKMS has ground to make up: its adjusted EBIT margin was 5.8% over nine months, against a full-year guide of up to 6.5% and a medium-term target above 7%. The company itself put the shortfall down to the ramp-up of new construction projects and the extra costs of the spin-off.

The order book was already deep. At €20.1bn at the end of June, the backlog equalled about eight years of sales at the nine-month run rate of €1,890m, before these frigates, Canada's up to twelve submarines or India's six. Capacity is the constraint, and TKMS has said as much by withdrawing its bid for German Naval Yards Kiel and looking at Navantia's shipyards in Spain. An order that runs on structures already in place adds work without adding to that strain.

Management's own record argues for patience on the margin. A year ago its guidance implied a margin below the 6% it had just earned; the outlook has since been raised twice, to up to 6.5%, yet the nine-month margin of 5.8% was still below the year before. Hensoldt shows the same constraint: it is building radar capacity to more than three times its 2021 level, because capacity, more than demand, sets the pace.

The risk is cost. A series with its first delivery three years away and the last well into the next decade gives inflation and supply chains a long time to bite, and the release says nothing about how price changes are shared with the customer. The full-year figures should show whether the margin is moving towards 7% as the series work builds up.

Sources we read for this take

Company: Contract release for four additional MEKO A-200 DEU frigates (17 Nov 2026); budget committee release (8 Oct 2026); nine-month 2025/26 results release (12 Aug 2026)

Track record: FY2024/25 guidance, from our take of 9 Dec 2025

Peers cross-read: Hensoldt Capital Markets Day (Lux Opes take, 11 Nov 2025)

Our earlier take: Payments, commodities and eagles (13 Aug 2026)


Zurich Insurance (ZURN Switzerland): The Beazley return now leans on revenue Zurich has yet to win

● NEUTRAL

Capital synergies go to USD 1.8bn from about USD 1bn and revenue synergies to about USD 1.5bn. On Zurich's own footnote, the promised return above 12% needs both.

Price 646.60  ·  P/E next yr 16.4x  ·  Consensus upside -3.8%

Zurich's higher Beazley targets make the deal look better on paper, but most of the improvement rests on revenue it has not yet won and capital it has not yet released. Six weeks after completing the deal, Zurich raised all three synergy figures at its investor day. Capital synergies within two years go to USD 1.8bn from about USD 1bn, medium-term revenue opportunities to about USD 1.5bn from at least USD 1bn, and cost synergies by 2029 to more than USD 150m. The promise attached is a medium-term return above 12% and mid-single-digit accretion to 2027 core earnings per share.

The footnote shows how that return is built. Zurich takes Beazley's USD 0.9bn profit after tax for 2025, adds USD 150m of cost savings and a 15% margin on USD 1.5bn of new revenue, taxed at 26%, and divides by USD 9.4bn: the USD 10.9bn price, less the USD 1.8bn of capital synergies, plus USD 0.3bn of deal and integration costs. On our arithmetic that gives about 12.5%. Take out the revenue synergies and it falls to about 10.8%. Use the March estimate for capital synergies as well and it drops below 10%.

So the raised figures carry the case, and they are of different quality. The capital piece is the firmer one: USD 0.5bn from capital optimisation, USD 0.6bn from risk diversification and USD 0.7bn from funding efficiency, mostly a matter of models and structures inside a group whose solvency ratio is estimated at 271% against a 160% floor. The revenue piece rests on clients the two groups share, on putting Zurich's products and capacity through Beazley's Lloyd's platform, and on cyber. None of that revenue is booked yet, and the 15% margin is an assumption Zurich sets for itself.

The rest of the group gives Zurich room. Core return on equity was 27.1% in the first half, against a target above 23%, and core EPS grew 11.5% against a target above 9%. Before Beazley, the plan implies 2027 core EPS above USD 51.9, from USD 40.1 in 2024. The 2027 targets do not depend on the deal.

The pricing backdrop is turning against that assumption. Swiss Re reported that its new business margin fell 28% to $2.8bn over nine months as P&C renewals became more competitive, and Hannover Re saw P&C revenue fall 4.9%. Zurich itself had commercial rates down 1% in the first half. The 15% margin on new specialty revenue is being assumed just as the market softens.

What happens to the USD 1.8bn now matters most. Freed capital lifts returns only once it is put to work in growth or handed back to shareholders, and Zurich has not yet said which. Until it does, part of the 12% sits in the denominator and nowhere else.

Sources we read for this take

Company: Release on Beazley synergies (17 Nov 2026); Investor Day 2026 presentation (17 Nov 2026)

Peers cross-read: Swiss Re and Hannover Re nine-month 2026 results (Lux Opes takes, 10 Nov 2026)

Our earlier take: Payments, commodities and eagles (13 Aug 2026)


Vusion (VU France): Pricer comes cheap, and the value sits in its 28,000 stores

● NEUTRAL

SEK 6.00 a share values Pricer at about 0.5x sales and 7.5x adjusted operating profit. Its largest holder, with 14.15%, is bound to accept even if a higher offer comes.

Price 144.85  ·  P/E next yr 17.2x  ·  Consensus upside 46.1%

Vusion is paying a low price for a rival that has just repaired its margins. The SEK 6.00 cash offer values Pricer at SEK 980m, or about SEK 1.0bn including its small net debt, against SEK 2,051m of sales and SEK 134.5m of adjusted operating profit over the last twelve months. That is about 0.5x sales and 7.5x adjusted EBIT for a company whose gross margin rose to 28.0% over nine months from 22.0%, with a third-quarter adjusted EBIT margin of 12.9%.

Vusion plans no cost cuts. It says it does not intend material changes to operations, locations, management or staff, and Pricer's board says its customers will keep being supplied and supported. What Vusion buys is an installed base of 380 million labels in 28,000 stores, customers such as Sobeys in Canada and Orange in France, and one competitor fewer in a market Pricer's CEO described a month ago as one of "intensifying competition and persistent price pressure". Pricer's sales fell 6.2% in nine months as Carrefour volumes dropped, while its orders rose 13%.

For Vusion the deal is small, about a tenth of revenue, and well timed. Our September take noted that its first-half orders fell 22%. Pricer brings SEK 2,064m of orders over twelve months and a customer base for Vusion's cloud, computer vision and retail media tools. Pricer's recurring revenue is still only SEK 100.6m over nine months, so most of what Vusion can add lies in that cross-sell.

Vusion's own order book explains the timing. In the first half its order intake fell 22% to €681m, and the rolling twelve-month total of €1,511m gave a book-to-bill of roughly 0.9x as the Walmart rollout wound down. Pricer's base of 28,000 stores gives Vusion customers for its cloud and services while its own intake refills, which matters more than Pricer's earnings.

Completion looks likely. The board backs the offer unanimously, a fairness opinion backs the price, and Sterling's 14.15% stake is committed even against a higher bid. What remains is 90% acceptance and competition approvals on terms Vusion accepts.

Sources we read for this take

Target: Pricer board statement on the Vusion offer (17 Nov 2026); Pricer Q3 2026 interim report (22 Oct 2026)

Track record: Vusion H1 2026 orders, from our take of 22 Sep 2026

Our earlier take: Pharma, CMDs and a lot of defense (22 Sep 2026)


Verallia (VRLA France): The 2029 margin target only works if glass prices stop falling

● NEUTRAL

The bigger cost plan is worth about €165m by 2029, against a step of about €125m to a 25% margin. In the first nine months of 2026, price and mix took €32m and cancelled most of the savings.

Price 17.52  ·  P/E next yr 16.3x  ·  Consensus upside 19.8%

Verallia's new plan asks investors to believe one thing above all: that the price of glass stops falling. The 2029 target of a 24-26% adjusted EBITDA margin, from 20.7% over nine months of 2026, rests on volumes growing 0-1% a year and a "neutral spread", meaning selling prices and mix move in line with costs. Management says the plan "revolves around what we control". The cost side is controllable. The spread is not, and it has been negative all year.

The arithmetic is tight. Raising the Performance Action Plan from 2.0% to at least 2.5% of cash production costs is worth about €55m a year, since this year's 2.2% delivered €37m in nine months. Over three years that is about €165m. Guidance for 2026 is about €700m of adjusted EBITDA, around 21% of sales. A 25% margin on sales of about €3.3bn means about €825m, a step of about €125m. The cost plan covers that with roughly €40m to spare, and that cushion is all that stands between the target and any price given back to customers.

That leakage is what happened in 2026. Over nine months the plan saved €37m while the price/mix-cost spread cost €32m, and in the third quarter the spread, €15m negative, was larger than the €11m of savings. The price effect "gradually faded over the course of the year" and mix is still unfavourable, mainly in still and sparkling wine. A plan that needs the spread at zero from next year is a bet that pricing turns in a market with 0-1% demand growth, which the company itself calls difficult.

The cash targets are easier to believe. €750-850m of free cash flow over 2027-29 compares with €485m in 2024-26 and about €220m guided for this year, helped by capex of 8-9% of sales with no new capacity and by working capital. Leverage below 2x by 2028, from 2.5x in September, follows if EBITDA merely holds. Two lines soften that promise: M&A "is an option", with any pause in deleveraging called temporary, and the dividend floor of €1 a share may be paid partly in shares, which protects cash but dilutes holders who take the paper.

Vidrala is the reference point. Over the same nine months of 2026 its sales rose 2% and its EBITDA margin widened to 29.5%, with Europe subdued and growth coming from South America, and it credits cost control for the margin. A glass maker can protect margins in this market, then, and Verallia's 24-26% target still sits well below what its Spanish peer already earns. The difference is where the help comes from: Vidrala found volume outside Europe, while Verallia's plan needs European prices to stop falling.

The first proof comes with the full-year results on 17 February. A 2027 guide of at least €740m of adjusted EBITDA would put the plan on its path in year one. A fourth quarter with the spread still negative would say the margin target depends on savings that customers keep taking back.

Sources we read for this take

Company: Capital Markets Day release, "Verallia Beyond" (18 Nov 2026); Q3 2026 release (27 Oct 2026)

Peers cross-read: Vidrala nine-month 2026 results (Oct 2026)

Our earlier take: Soccer, music and beaches (12 Feb 2025)


PFISTERER (PFSE Germany): The year is safe, 2027 hangs on fourth-quarter orders

● NEUTRAL

Revenue guidance is safe and orders are the open question. Meeting order guidance needs about €143m in Q4, 22% above last year, and the CFO declined to give October.

Price 61.90  ·  P/E next yr 17.5x  ·  Consensus upside 68.6%

The raised revenue guidance is safe. What matters now is whether orders grow again. PFISTERER expects the upper half of its 12–17% growth range, €515–526m, which needs only 6–16% growth in the fourth quarter after 12.5% in the third. Over nine months revenue is up 17.5% while orders are down 5.8%, and that gap cannot last. Orders at last year's €550m, as guided, need about €143m in the fourth quarter, 22% more than a year ago and level with the third quarter. The CFO would not give October orders, saying the guidance "should give you also a pretty clear view". That is confident language for a number he chose not to show.

The weak spot is the Middle East and India. Orders there fell 25% over nine months to €83m, and overhead line orders fell 24%, while the region's revenue grew 37%. That backlog is being worked down faster than it is refilled. Elsewhere the picture has improved. Outside the Middle East and India, revenue grew about 12%, against less than 4% a year earlier, and high voltage accessories, the largest business, kept a book-to-bill of 1.16.

The third-quarter margin dip, from 19.1% to 17.0%, matters less. Management attributes €3.5m to IT consultants, a warranty provision, a rebranding project and currency effects. Adding that back gives about 19.8%, and the gross margin rose to 40.7%. Some of it will recur: the CFO said warranty provisions "are never predictable", and the digitalisation spending continues. His margin promise is undemanding. A full year above 2025's 17.8% needs only about 13.5% in the fourth quarter. Nine-month EBITDA also contains €4.9m of insurance money for the 2024 damage at the Wunsiedel plant.

Growth is absorbing cash, and rivals are adding capacity. Operating cash flow was −€8.8m in the quarter, and net cash of €19.2m at the end of 2025 has become €35.2m of net debt, which is easily carried at this level of EBITDA. Insulator lead times are down from more than a year to the high 30s in weeks, which will test pricing. Management believes it can still pass costs on. In October, Nexans called its European accessories plants "saturated" and said it will add about 39% to medium voltage accessory capacity by 2028. That is PFISTERER's slowest segment, with revenue up 2% to €45m.

The test comes with the full-year results on 24 March: fourth-quarter orders of at least €143m, and ideally the first HVDC order, which management now expects in 2027. Without them, growth in 2027 will slow towards the order trend.

Sources we read for this take

Company: Q3 2026 release, quarterly statement and webcast slides (18 Nov 2026); FY2025 results webcast (15 Apr 2026)

Calls: PFISTERER Q3 2026 call (18 Nov 2026); Q2 2026 call (19 Aug 2026)

Peers cross-read: Nexans Q3 2026 call (22 Oct 2026)

Our earlier take: Specialty chems, hospitals and troubled bakeries (11 Aug 2026)